CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $29.13M, above the global median of $18.73M
- FinancialsAltman Z-Score 4.34: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.74%Below 5Y avg (4.26%)
Annual Rate
CNY 0.20Paid annual
Payout Ratio
0.0%Sustainable
Payback Period
57.0 yr
Last Ex-Dividend
Jul 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.72BCNY1.00B · vs all stocks (USD)
Revenue (TTM)
2.51BCNY374.19M · vs all stocks (USD)
Profit Margin
-10.36%Beta
0.2390xvs all stocks
52-Week Change
-26.31%vs all stocks
Market Capitalization
6.72BCNY1.00B · vs all stocks (USD)
Enterprise Value
4.24BCNY633.68M · vs all stocks (USD)
Forward P/E
4.86xPrice to Sales (TTM)
2.68xPrice to Book (MRQ)
1.72xEnterprise to Revenue
1.69xEnterprise to EBITDA
-32.03xGross Margin
53.09%Profit Margin
-10.36%Operating Margin
-7.98%Return on Assets (TTM)
-3.26%Return on Equity (TTM)
-6.70%Revenue (TTM)
2.51BCNY374.19M · vs all stocks (USD)
Revenue per Share (TTM)
4.33CNYUpdated Sep 21, 2026Quarterly Revenue Growth
1.10%Gross Profit (TTM)
1.15BCNY171.26M · vs all stocks (USD)
EBITDA (TTM)
-132.49MCNY-19.79M · vs all stocks (USD)
Net Income (TTM)
-259.67MCNY-38.78M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.43%Operating Cash Flow (TTM)
250.89MCNY37.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
195.07MCNY29.13M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
1.74%vs all stocks
5-Year Average Dividend Yield
4.26%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
152.37MCNYFY2025 · Dec 31, 2025Revenue
2.32BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.43BCNYFY2025 · Dec 31, 2025Gross Profit
884.35MCNYFY2025 · Dec 31, 2025Operating Income
-212.03MCNY-31.66M · vs all stocks (USD)
Pre-tax Income
-271.15MCNYFY2025 · Dec 31, 2025Income Tax Expense
25.92MCNYFY2025 · Dec 31, 2025Net Income
-297.07MCNYFY2025 · Dec 31, 2025EBIT
-267.46MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.11MCNYFY2025 · Dec 31, 2025Research & Development
111.11MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
581.28MCNYFY2025 · Dec 31, 2025Other Operating Expenses
43.71MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.69MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
585.97MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
585.97MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-297.07MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
39.25MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
334.33MCNYFY2025 · Dec 31, 2025Free Cash Flow
238.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
849.92MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-297.07MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.44MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
421.49MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
201.48MCNYFY2025 · Dec 31, 2025Capital Expenditures
-95.58MCNYFY2025 · Dec 31, 2025Purchase of Investments
-9.81BCNYFY2025 · Dec 31, 2025Sale of Investments
9.35BCNYFY2025 · Dec 31, 2025Other Investing Activity
-62.94KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-552.62MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
118.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-13.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-292.12MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-191.25MCNYFY2025 · Dec 31, 2025Shares Outstanding
584.00MSharesUpdated Sep 21, 2026Float Shares
250.93MSharesUpdated Sep 21, 2026% Held by Insiders
57.36%vs all stocks
% Held by Institutions
4.36%vs all stocks
Total Cash (MRQ)
2.68BCNY399.68M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.58CNYUpdated Sep 21, 2026Total Debt (MRQ)
191.62MCNY28.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0470xCurrent Ratio (MRQ)
3.47xBook Value per Share (MRQ)
6.71CNYUpdated Sep 21, 2026Total Assets
5.33BCNY795.68M · vs all stocks (USD)
Total Current Assets
3.50BCNYFY2025 · Dec 31, 2025Total Liabilities
1.34BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.83BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
186.14MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.15BCNYFY2025 · Dec 31, 2025Cash
848.18MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.64MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
852.82MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.76BCNYFY2025 · Dec 31, 2025Accounts Receivable
62.15MCNYFY2025 · Dec 31, 2025Inventory
617.43MCNYFY2025 · Dec 31, 2025Accounts Payable
421.62MCNYFY2025 · Dec 31, 2025Short-term Debt
112.93MCNYFY2025 · Dec 31, 2025Other Current Liabilities
9.80MCNYFY2025 · Dec 31, 2025Long-term Debt
3.00MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.30MCNYFY2025 · Dec 31, 2025Common Stock (Book)
584.00MCNYFY2025 · Dec 31, 2025Retained Earnings
2.02BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.99BCNY595.93M · vs all stocks (USD)
52-Week Low
11.04CNYUpdated Sep 21, 202652-Week High
15.72CNYUpdated Sep 21, 202652-Week Change
-26.31%vs all stocks
Beta
0.2390xvs all stocks
50-Day MA
12.84CNYUpdated Sep 21, 2026200-Day MA
13.28CNYUpdated Sep 21, 2026Avg 10-Day Volume
3.73MSharesUpdated Sep 21, 2026Avg 30-Day Volume
5.70MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.4400CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.53Profit Margin: -0.10
Financial Health
Altman Z-Score 4.34: safe zoneNotable
Altman Z-Score: 4.34
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $29.13M, above the global median of $18.73MNotable
Levered free cash flow (USD): 29,129,621.515Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sino Medical Sciences Technology Inc.
Tier 1ProductionApproval-Gated PipelineRule
0009K0
Tier 1ProductionApproval-Gated PipelineRuleRisk
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Kanghua Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Janux Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk